Nifty settles below 24,600 level; broader mkt underperforms; pharma shares tumble

The headline equity benchmarks ended with significant losses today, as investors turned cautious following the U.S. imposition of steep tariffs on multiple trade partners and the reaffirmation of a 25% import duty on Indian goods. Investors were also monitoring the ongoing earnings season. The Nifty settled below the 24,600 level after hitting the days high of 24,784.15 in mid-morning trade.

Barring the Nifty FMCG index, all the other sectoral indices on the NSE ended in red.

As per provisional closing data, the barometer index, the S&P BSE Sensex declined 585.67 points or 0.72% to 80,599.91. The Nifty 50 index lost 203 points or 0.82% to 24,565.35.

The broader market underperformed the frontline indices. The S&P BSE Mid-Cap index slipped 1.37% and the S&P BSE Small-Cap index declined 1.59%.

The market breadth was weak. On the BSE, 1,307 shares rose and 2,711 shares fell. A total of 151 shares were unchanged.

The NSE’s India VIX, a gauge of the market’s expectation of volatility over the near term, rallied 3.74% to 11.98

Related Posts

Can a drug licence be suspended before a hearing? Karnataka HC explains rule

NEW DELHI: Can a drug licensing authority suspend a pharmaceutical distributor’s licence while issuing a show-cause notice, before considering its response? The Karnataka high court has said the procedure under…

A Boy survives 18th Floor Fall, thanks to Yashoda Medicity

Multispecialty Hospital averted a Certain Death, underlining High Benchmark of its Critical Care Delhi/NCR: By the look of it, it seemed a certain death. A teenager (15) who fell from…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Can a drug licence be suspended before a hearing? Karnataka HC explains rule

Can a drug licence be suspended before a hearing? Karnataka HC explains rule

A Boy survives 18th Floor Fall, thanks to Yashoda Medicity

A Boy survives 18th Floor Fall, thanks to Yashoda Medicity

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

‘Bone Bonding’ between Mothers and Children, thanks to Meticulous Bone Grafting

‘Bone Bonding’ between Mothers and Children, thanks to Meticulous Bone Grafting